Glioblastoma

Handbook of Clinical Neurology

Volumn 105, Issue , 2012, Pages 485-506

  Penas Prado, Marta ^a   Armstrong, Terri S ^b   Gilbert, Mark R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855531972     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53502-3.00004-5     Document Type: Chapter

References (227)

1. Agnelli G., Piovella F., Buoncristiani P., et al. Enoxaparin plus compression stockings compared with compression n stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998, 339:80-85.
2. Andersen A.P. Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol 1978, 17:475-484.
3. Andratschke N., Grosu A.L., Molls M., et al. Perspectives in the treatment of malignant gliomas in adults. Anticancer Res 2001, 21:3541-3550.
4. Apuzzo M., Chandrasoma P., Cohen D., et al. Computed imaging stereotaxy: experience and perspective related to 500 procedures applied to brain masses. Neurosurgery 1987, 20:930-937.
5. Armstrong T.S., Kanusky J.T., Gilbert M.R. Seize the moment to learn about epilepsy in people with cancer. Clin J Oncol Nurs 2003, 7:163-169.
6. Armstrong T.S., Mendoza T., Gning I., et al. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol 2006, 80:27-35.
7. Auguste K.I., Quinones-Hinojosa A., Berger M.S. Efficacy of mechanical prophylaxis for venous thromboembolism in patients with brain tumors. Neurosurg Focus 2004, 17:E3.
8. Barker F.G., Chang S.N., Huhn S.L., et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 1997, 80:936-941.
9. Barker F.G., Chang S.N., Larson D.A., et al. Age and radiation response in glioblastoma multiforme. Neurosurgery 2001, 49:1288-1297.
10. Barnett G.H. The role of image-guided technology in the surgical planning and resection of gliomas. J Neurooncol 1999, 42:247-258.
11. Batchelor T.T., Byrne T.N. Supportive care of brain tumor patients. Hematol Oncol Clin North Am 2006, 20:1337-1361.
12. Batchelor T., DeAngelis L.M. Medical management of cerebral metastases. Neurosurg Clin N Am 1996, 7:435-446.
13. Batchelor T., Sorensen A., Ancukiewicz M., et al. A phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2007, 25:2001.
14. Bauman G.S., Gaspar L.E., Fisher B.J., et al. A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1994, 29:835-839.
15. Baumgartner K. Neurocognitive changes in cancer patients. Semin Oncol Nurs 2004, 20:284-290.
16. Beaumont A., Whittle I.R. The pathogenesis of tumour associated epilepsy. Acta Neurochir (Wien) 2000, 142:1-15.
17. Berger M., Leibel S., Bruner J., et al. Primary cerebral tumors. Cancer in the Nervous System 2002, 75-148. Oxford University Press, New York. V. Levin (Ed.).
18. Black P., Alexander E., Martin C., et al. Craniotomy for tumor treatment in an intraoperative magnetic resonance imaging unit. Neurosurgery 1999, 45:423-431.
19. Bleehen N.M., Stenning S.P. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991, 64:769-774.
20. Bode U., Buchen S., Janssen G., et al. Results of a phase II trial of h-R3 monoclonal antibody (nimotuzumab) in the treatment of resistant or relapsed high-grade gliomas in children and adolescents. J Clin Oncol 2006, 24:1522.
21. Brem H., Piantadosi S., Burger P.C., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet 1995, 345:1008-1012.
22. Brown P.D., Buckner J.C., O'Fallon J.R., et al. Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the Folstein mini-mental state examination. J Clin Oncol 2003, 21:2519-2524.
23. Brown P.D., Ballman K.V., Rummans T.A., et al. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol 2006, 76:283-291.
24. Bruera E., Driver L., Barnes E.A., et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003, 21:4439-4443.
25. Buckner J.C. Factors influencing survival in high-grade gliomas. Semin Oncol 2003, 30:10-14.
26. Butler J.M., Rapp S.R., Shaw E.G. Managing the cognitive effects of brain tumor radiation therapy. Curr Treat Options Oncol 2006, 7:517-523.
27. Butowski N.A., Sneed P.K., Chang S.M. Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol 2006, 24:1273-1280.
28. Cao Y., Sundgren P.C., Tsien C.L., et al. Physiologic and metabolic magnetic resonance imaging in gliomas. J Clin Oncol 2006, 24:1228-1235.
29. Carpentier A.F., Meng Y. Recent advances in immunotherapy for human glioma. Curr Opin Oncol 2006, 18:631-636.
30. Cascino G.D. Epilepsy and brain tumors: implications for treatment. Epilepsia 1990, 31:S37-S44.
31. Central Brain Tumor Registry of the United States (CBTRUS) Statistical Report: Primary Brain Tumors in the United States, 1998-2002 Online. Available:, (accessed 4 March 2011). http://www.cbtrus.org/reports//2005-2006/2006report.pdf.
32. Chakravarti A., Berkey B., Robins H., et al. An update of phase II results from RTOG 0211: a phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma. J Clin Oncol 2006, 24:1527.
33. Chan A.T., Atiemo A., Diran L.K., et al. Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J Thromb Thrombolysis 1999, 8:139-142.
34. Chang S.M., Kuhn J.G., Rizzo J., et al. Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 1998, 16:2188-2194.
35. Chen T.C., Su S., Fry D., et al. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer 2003, 97:2363-2373.
36. Chen C.Y., Lirng J.F., Chan W.P., et al. Proton magnetic resonance spectroscopy-guided biopsy for cerebral glial tumors. J Formos Med Assoc 2004, 103:448-458.
37. Cheruku R., Tapazoglou E., Ensley J., et al. The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer 1991, 68:2621-2624.
38. Cloughesy T.F., Kuhn J., Robins H.I., et al. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2005, 23:6647-6656.
39. Cloughesy T.F., Wen P.Y., Robins H.I., et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2006, 24:3651-3656.
40. Cohen N., Strauss G., Lew R., et al. Should prophylactic anticonvulsants be administered to patients with newly-diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 1988, 6:1621-1624.
41. Combs S.E., Heeger S., Haselmann R., et al. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) - phase I/II trial: study protocol. BMC Cancer 2006, 6:133.
42. Conrad C., Friedman H., Reardon D., et al. A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2004, 22:1512.
43. Couldwell W.T., Hinton D.R., Surnock A.A., et al. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. Clin Cancer Res 1996, 2:619-622.
44. Curran W.J., Scott C.B., Horton J., et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993, 85:704-710.
45. Curtin J.F., King G.D., Candolfi M., et al. Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr Top Med Chem 2005, 5:1151-1170.
46. Cutter J.L., Kurozumi K., Chiocca E.A., et al. Gene therapeutics: the future of brain tumor therapy?. Expert Rev Anticancer Ther 2006, 6:1053-1064.
47. De Groot J., Gilbert M., Hess K., et al. Phase II study of combination carboplatin and erlotinib in patients with recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:2024.
48. De Santis A., Villani R., Sinisi M., et al. Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia 2002, 43:175-182.
49. Desjardins A., Reardon D., Quinn J., et al. Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas. J Clin Oncol 2006, 24:1573.
50. Dhami M.S., Bona R.D., Calogero J.A., et al. Venous thromboembolism and high grade gliomas. Thromb Haemost 1993, 70:393-396.
51. Dickinson L.D., Miller L.D., Patel C.P., et al. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 1998, 43:1074-1081.
52. Dresemann G., Hosius C., Nikolova Z., et al. Single center phase ii trial analysing the role of imatinib/hydroxyurea in patients (pts) with pretreated non-progressive glioblastoma (GBM) as maintenance therapy. J Clin Oncol 2007, 25:2055.
53. Eastman A., Perez R.P. New targets and challenges in the molecular therapeutics of cancer. Br J Clin Pharmacol 2006, 62:5-14.
54. Edman J.C., Kovacs J.A., Masur H., et al. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988, 334:519-522.
55. Faithfull S. Fatigue in patients receiving radiotherapy. Prof Nurse 1998, 13:459-461.
56. Fine H.A., Dear K.B., Loeffler J.S., et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993, 71:2585-2597.
57. Fine H.A., Figg W.D., Jaeckle K., et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000, 18:708-715.
58. Fine H.A., Wen P.Y., Maher E.A., et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 2003, 21:2299-2304.
59. Fine H.A., Kim L., Royce C., et al. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol 2005, 23:1504.
60. Ford J.M., Stenning S.P., Boote D.J., et al. A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma. Clin Oncol (R Coll Radiol) 1997, 9:20-24.
61. Forsyth P.A., Posner J.B. Headaches in patients with brain tumors: a study of 111 patients. Neurology 1993, 43:1678-1683.
62. Forsyth P.A., Weaver S., Fulton D., et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 2003, 30:106-112.
63. Fox S.W., Mitchell S.A., Booth-Jones M. Cognitive impairment in patients with brain tumors: assessment and intervention in the clinic setting. Clin J Oncol Nurs 2006, 10:169-176.
64. Foy P.M., Chadwick D.W., Rajgopalan N., et al. Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy?. J Neurol Neurosurg Psychiatry 1992, 55:753-757.
65. Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740.
66. Galanis E., Buckner J.C., Maurer M.J., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005, 23:5294-5304.
67. Galanis E., Jaeckle K., Maurer M.J., et al. N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM). J Clin Oncol 2007, 25:2004.
68. Galicich J.H., French L.A., Melby J.C. Use of dexamethasone in the treatment of cerebral edema associated with brain tumors. Lancet 1961, 81:46-53.
69. Gerber D.E., Grossman S.A., Streiff M.B. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 2006, 24:1310-1318.
70. Gilbert M., Gaupp P., Liu V., et al. A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), lonafarnib (Sarazar, SCH66336) in recurrent glioblastoma. J Clin Oncol 2006, 24:1556.
71. Gilbert M.R., Wang M., Aldape K., et al. RTOG 0625: a phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2009, 27:2011.
72. Glantz M.J., Cole B.F., Forsyth P.A., et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54:1886-1893.
73. Gleason J., Case D., Rapp S., et al. Symptom clusters in newly-diagnosed brain tumor patients. ASCO Annual Meeting Proceedings, Part 1. J Clin Oncol 2006, 24:489s.
74. Gnanalingham K.K., Holland J.P. Attitudes to the use of prophylaxis for thrombo-embolism in neurosurgical patients. J Clin Neurosci 2003, 10:467-469.
75. Goldring S., Gregorie E.M. Surgical management of epilepsy using epidural recordings to localize the seizure focus. Review of 100 cases. J Neurosurg 1984, 60:457-466.
76. Graves E.E., Nelson S.J., Vigneron D.B., et al. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. Am J Neuroradiol 2001, 22:613-624.
77. Groves M.D., Puduvalli V.K., Hess K.R., et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002, 20:1383-1388.
78. Groves M.D., Puduvalli V.K., Chang S.M., et al. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 2007, 81:271-277.
79. Haberg A., Kvistad K.A., Unsgard G., et al. Preoperative blood oxygen level-dependent functional magnetic resonance imaging in patients with primary brain tumors: clinical application and outcome. Neurosurgery 2004, 54:902-914.
80. Hammoud M.A., Ligon Bl, elSouki R., et al. Use of intraoperative ultrasound for localizing tumors and determining the extent of resection: a comparative study with magnetic resonance imaging. J Neurosurg 1996, 84:737-741.
81. Hanna A., Sledge G., Mayer M.L., et al. A phase II study of methylphenidate for the treatment of fatigue. Support Care Cancer 2006, 14:210-215.
82. Hau P., Bogdahn U., Olyushin V., et al. Results of a phase IIb study in recurrent or refractory glioblastoma patients with the TGF-beta-2 inhibitor AP 12009. J Clin Oncol 2007, 25:12521.
83. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
84. Henson J.W., Jalaj K.J., Walker R.W., et al. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol 1991, 48:406-409.
85. Hess K.R. Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol 1999, 42:227-231.
86. Hickok J.T., Roscoe J.A., Morrow G.R., et al. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer 2005, 104:1772-1778.
87. Hill C., Hunter S.B., Brat D.J. Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv Anat Pathol 2003, 10:212-217.
88. Hoegler D.B., Davey P. A prospective study of short course radiotherapy in elderly patients with malignant glioma. J Neurooncol 1997, 33:201-204.
89. Holland K.D. Efficacy, pharmacology, and adverse effects of antiepileptic drugs. Neurol Clin 2001, 19:313-345.
90. Horlander K.T., Mannino D.M., Leeper K.V. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med 2003, 163:1711-1717.
91. Iorio A., Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med 2000, 160:2327-2332.
92. Jackson R.J., Fuller G.N., Abi-Said D., et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-oncol 2001, 3:193-200.
93. Jeremic B., Milicic B., Grujicic D., et al. Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol 2003, 129:477-484.
94. Jeremic B., Milicic B., Grujicic D., et al. Clinical prognostic factors in patients with malignant glioma treated with combined modality approach. Am J Clin Oncol 2004, 27:195-204.
95. Jiang H., Alonso M.M., Gomez-Manzano C., et al. Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. Expert Rev Anticancer Ther 2006, 6:1585-1592.
96. Kaal E.C., Vecht C.J. The management of brain edema in brain tumors. Curr Opin Oncol 2004, 16:593-600.
97. Kardosh A., Blumenthal M., Wang W.J., et al. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther 2004, 3:55-62.
98. Kim J., Gildenberg P. Stereotactic biopsy. Textbook of Stereotactic and Functional Neurosurgery 1998, 387-396. McGraw-Hill, New York. P. Gildenberg, R.R. Tasker (Eds.).
99. Kimura T., Sako K., Tohyama Y., et al. Diagnosis and treatment of progressive space-occupying radiation necrosis following stereotactic radiosurgery for brain metastasis: value of proton magnetic resonance spectroscopy. Acta Neurochir (Wien) 2003, 145:557-564.
100. Kita M., Okawa T., Tanaka M., et al. Radiotherapy of malignant glioma - prospective randomized clinical study of whole brain vs local irradiation. Gan No Rinsho 1989, 35:1289-1294.
101. Pathology and Genetics of Tumours of the Nervous System. World Health Organization Classification of Tumours 2000, IARC Press, Lyons. P. Kleihues, W.K. Cavenee (Eds.).
102. Koehler P.J. Use of corticosteroids in neuro-oncology. Anticancer Drugs 1995, 6:19-33.
103. Kovacs J., Gill V.J., Meshnick S., et al. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 2001, 286:2450-2460.
104. Kristiansen K., Hagen S., Kollevold T., et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981, 47:649-652.
105. Kucharczyk W., Henkelman R.M. Visibility of calcium on MR and CT: can MR show calcium that CT cannot?. Am J Neuroradiol 1994, 15:1145-1148.
106. Kuijlen J.M., Teernstra O.P., Kessels A.G., et al. Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a meta-analysis. Seizure 1996, 5:291-298.
107. Kunwar S., Prados M.D., Chang S.M., et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007, 25:837-844.
108. Lacroix M., Abi-Said D., Fourney D.R., et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001, 95:190-198.
109. Lamborn K.R., Chang S.M., Prados M.D. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-oncol 2004, 6:227-235.
110. Laperriere N., Zuraw L., Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002, 64:259-273.
111. Laylon J.A., Bavrielli A. Elevated intracranial pressure. Textbook of Neurointensive Care 2004, 709-732. Saunders, Philadelphia. J.A. Laylon, A. Gabrielli, W.A. Friedman (Eds.).
112. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349:146-153.
113. Leeds N.E., Kumar A.J., Jackson E.F. Diagnostic imaging. Cancer in the Nervous System 2002, 1-59. Oxford University Press, Oxford. V.A. Levin (Ed.).
114. Lesniak M.S., Langer R., Brem H. Drug delivery to tumors of the central nervous system. Curr Neurol Neurosci Rep 2001, 1:210-216.
115. Levin V.A., Phuphanich S., Yung W.K., et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 2006, 78:295-302.
116. Liang B., Thornton A., Sandler H., et al. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 1991, 75:559-563.
117. Lichy M.P., Bachert P., Henze M., et al. Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy. Neuroradiology 2004, 46:126-129.
118. Lieberman F., Cloughesy T., Fine H., et al. NABTC phase I-II study of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. Proc Am Soc Clin Oncol 2004, 23:1510.
119. Liigant A., Haldre S., Oun A., et al. Seizure disorders in patients with brain tumors. Eur Neurol 2001, 45:46-51.
120. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol (Berl) 2007, 114:97-109.
121. Lovely M.P. Symptom management of brain tumor patients. Semin Oncol Nurs 2004, 20:273-283.
122. Lovely M.P., Miakowski C., Doss M. Relationship between fatigue and quality of life in patients with glioblastoma multiforme. Oncol Nurs Forum 1999, 26:921-925.
123. Macleod A.D. Methylphenidate in terminal depression. J Pain Symptom Manage 1998, 16:193-198.
124. Mahindra A.K., Grossman S.A. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neurooncol 2003, 63:263-270.
125. Marosi C., Vedadinejad M., Haberler C., et al. Imatinib mesylate in the treatment of patients with recurrent high grade gliomas expressing PDGF-R. J Clin Oncol 2006, 24:1526.
126. Marras L.C., Geerts W.H., Perry J.R. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000, 89:640-646.
127. Mathew B.S., Grossman S.A. Pneumocystis carinii pneumonia prophylaxis in HIV negative patients with primary CNS lymphoma. Cancer Treat Rev 2003, 29:105-119.
128. Mathijssen R.H., Sparreboom A., Dumez H., et al. Altered irinotecan metabolism in a patient receiving phenytoin. Anticancer Drugs 2002, 13:139-140.
129. Matz P.G., Cobbs C., Berger M.S. Intraoperative cortical mapping as a guide to the surgical resection of gliomas. J Neurooncol 1999, 42:233-245.
130. McKnight T.R., Lamborn K.R., Love T.D., et al. Correlation of magnetic resonance spectroscopic and growth characteristics within grades II and III gliomas. J Neurosurg 2007, 106:660-666.
131. Meyers C.A., Weitzner M.A., Valentine A.D., et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998, 16:2522-2527.
132. Meyers C.A., Hess K.R., Yung W.K., et al. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 2000, 18:646-650.
133. Morrow G.R., Shelke A.R., Roscoe J.A., et al. Management of cancer-related fatigue. Cancer Invest 2005, 23:229-239.
134. Nabors L., Rosenfeld S., Mikkelsen T., et al. NABTT 9911: a phase I trial of EMD 121974 for treatment of patients with recurrent malignant gliomas. Neuro-oncol 2004, 6:379.
135. Nelson D.F., Diener-West M., Horton J., et al. Combined modality approach to treatment of malignant gliomas - re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 1988, 6:279-284.
136. Nelson S.J., Huhn S., Vigneron D.B., et al. Volume MRI and MRSI techniques for the quantitation of treatment response in brain tumors: presentation of a detailed case study. J Magn Reson Imaging 1997, 7:1146-1152.
137. Newton H.B., Goldlust S.A., Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 2006, 78:99-102.
138. Nguyen T., Lassman A., Lis E., et al. A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme. J Clin Oncol 2006, 24:1507.
139. Nieder C., Adam M., Molls M., et al. Therapeutic options for recurrent high-grade glioma in adult patients: recent advances. Crit Rev Oncol Hematol 2006, 60:181-193.
140. Nimsky C., Ganslandt O., Fahlbusch R. Implementation of fiber tract navigation. Neurosurgery 2006, 58:ONS-292-ONS-303.
141. Norden A.D., Young G.S., Setayesh K., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70:779-787.
142. North J.B., Penhall R.K., Hanieh A., et al. Phenytoin and postoperative epilepsy. A double-blind study. J Neurosurg 1983, 58:672-677.
143. Ohgaki H., Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl) 2005, 109:93-108.
144. Ohgaki H., Dessen P., Jourde B., et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004, 64:6892-6899.
145. Osoba D., Aaronson N.K., Muller M., et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol 1997, 34:263-278.
146. Papadopoulos M.C., Saadoun S., Binder D.K., et al. Molecular mechanisms of brain tumor edema. Neuroscience 2004, 129:1011-1020.
147. Patel S.J., Shapiro W.R., Laske D.W., et al. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 2005, 56:1243-1252.
148. Penas-Prado M., Gilbert M.R. Molecularly targeted therapies for malignant gliomas: advances and challenges. Expert Rev Anticancer Ther 2007, 7:641-661.
149. Pereboom D., Brewer C., Suh G., et al. Phase II trial of erlotinib with temozolomide and concurrent radiation therapy in patients with newly diagnosed glioblastoma multiforme: final results. Neuro-oncol 2006, 8:448.
150. Perry J.R., Rogers L., Laperriere N., et al. PRODIGE: a phase III randomized placebo-controlled trial of thomboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. 2007 ASCO Annual Meeting Proceedings, Part 1. J Clin Oncol 2007, 25:18s.
151. Phillips H.S., Kharbanda S., Chen R., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
152. Phuphanich S., Supko J., Carson K.A., et al. Phase I trial of bortezomib in adults with recurrent malignant glioma. J Clin Oncol 2006, 24:1567.
153. Prados M., Chang S., Burton E., et al. Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. Eur J Cancer 2003, 1:33.
154. Prados M., Yung W., Wen P., et al. Phase I study of ZD1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium. Proc Am Soc Clin Oncol 2004, 23:1504.
155. Prados M.D., Chang S.M., Butowski N., et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009, 27:579-584.
156. Rabinov J.D., Lee P.L., Barker F.G., et al. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology 2002, 225:871-879.
157. Raizer J., Abrey L., Wen P., et al. A phase II trial of erlotinib (OSI-774) in patients (Pts) with recurrent malignant gliomas (MG) not on EIAEDs. Proc Am Soc Clin Oncol 2004, 23:1502.
158. Raymond E., Brandes A., Van Oosterom A., et al. Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC: NDDG/BTG Intergroup Study. J Clin Oncol 2004, 22:1501.
159. Reardon D.A., Egorin M.J., Quinn J.A., et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005, 23:9359-9368.
160. Reardon D., Quinn J., Rich J., et al. A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma. J Clin Oncol 2006, 24:1580.
161. Reardon D.A., Quinn J.A., Vredenburgh J.J., et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006, 12:860-868.
162. Reardon D., Fink K., Nabors B., et al. Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-009. J Clin Oncol 2007, 25:2002.
163. Rich J.N., Reardon D.A., Peery T., et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004, 22:133-142.
164. Rock J.P., Hearshen D., Scarpace L., et al. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 2002, 51:912-919.
165. Ruff R.L., Posner J.B. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 1983, 13:334-336.
166. Saconn P.A., Ip E., Rapp S., et al. Symptom clusters in irradiated brain tumor survivors. 2006 ASCO Annual Meeting Proceedings, Part 1. J Clin Oncol 2006, 24:488s.
167. Sadones J., Chaskis C., Joosens E., et al. A stratified phase II study of cetuximab for the treatment of recurrent glioblastoma multiforme: Preliminary results. J Clin Oncol 2006, 24:1558.
168. Sala F., Lanteri P. Brain surgery in motor areas: the invaluable assistance of intraoperative neurophysiological monitoring. J Neurosurg Sci 2003, 47:79-88.
169. Sampson J.H., Akabani G., Friedman A.H., et al. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus 2006, 20:E14.
170. Sandberg-Wollheim M., Malmstrom P., Stromblad L.G., et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991, 68:22-29.
171. Sansal I., Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004, 22:2954-2963.
172. Sathornsumetee S., Reardon D., Quinn J., et al. An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. J Clin Oncol 2006, 24:1560.
173. Sawaya R. Extent of resection in malignant gliomas: a critical summary. J Neurooncol 1999, 42:303-305.
174. Sawaya R., Highsmith R.F. Postoperative venous thromboembolism and brain tumors: Part III. Biochemical profile. J Neurooncol 1992, 14:113-118.
175. Sawaya R.E., Ligon B.L. Thromboembolic complications associated with brain tumors. J Neurooncol 1994, 22:173-181.
176. Sawaya R., Hammoud M., Schoppa D., et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 1998, 42:1044-1055.
177. Scheibel R.S., Meyers C.A., Levin V.A. Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol 1996, 30:61-69.
178. Schiff D. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. J Neurooncol 1996, 27:235-240.
179. Sciacca F.L., Ciusani E., Silvani A., et al. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res 2004, 10:1312-1317.
180. Scott C.B., Scarantino C., Urtasun R., et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998, 40:51-55.
181. See S.J., Levin V.A., Yung W.K., et al. 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro-oncol 2004, 6:253-258.
182. Semrad T.J., O'Donnell R., Wun T., et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007, 106:601-608.
183. Sepkowitz K.A., Brown A.E., Telzak E.E., et al. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992, 267:832-837.
184. Shapiro W.R., Green S.B., Burger P.C., et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 1989, 71:1-9.
185. Shaw E.G., Rosdhal R., D'Agostino R.B., et al. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 2006, 24:1415-1420.
186. Sirven J.I., Wingerchuk D.M., Drazkowski J.F., et al. Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 2004, 79:1489-1494.
187. Slivka A., Wen P.Y., Shea W.M., et al. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med 1993, 94:216-219.
188. Slotman B.J., Kralendonk J.H., van Alphen H.A., et al. Hypofractionated radiation therapy in patients with glioblastoma multiforme: results of treatment and impact of prognostic factors. Int J Radiat Oncol Biol Phys 1996, 34:895-898.
189. Smith J.S., Tachibana I., Passe S.M., et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001, 93:1246-1256.
190. Sood A., Barton D.L., Loprinzi C.L. Use of methylphenidate in patients with cancer. Am J Hosp Palliat Care 2006, 23:35-40.
191. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359:1011-1018.
192. Streiff M.B., Segal J., Grossman S.A., et al. ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer 2004, 100:1717-1723.
193. Stupp R., Dietrich P.Y., Ostermann Kraljevic S., et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002, 20:1375-1382.
194. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
195. Stupp R., Goldbrunner B., Neyns B., et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 2007, 25:2000.
196. Sugawara Y., Akechi T., Shima Y., et al. Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study. Palliat Med 2002, 16:261-263.
197. Tanwar M.K., Gilbert M.R., Holland E.C. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002, 62:4364-4368.
198. Taphoorn M.J., Schiphorst A.K., Snoek F.J., et al. Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol 1994, 36:48-54.
199. Thomas C.F., Limper A.H. Pneumocystis pneumonia: clinical presentation and diagnosis in patients with and without acquired immune deficiency syndrome. Semin Respir Infect 1998, 13:289-295.
200. Thomas C.F., Limper A.H. Pneumocystis pneumonia. N Engl J Med 2004, 350:2487-2498.
201. Thomas R., James N., Guerrero D., et al. Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. Radiother Oncol 1994, 33:113-116.
202. 6 -alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003, 88:1004-1011.
203. Uhm J., Ballman K., Giannini C., et al. Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma. Proc Am Soc Clin Oncol 2004, 23:1505.
204. Valtonen S., Timonen U., Toivanen P., et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997, 41:44-48.
205. van Breemen M.S., Vecht C.J. Optimal seizure management in brain tumor patients. Curr Neurol Neurosci Rep 2005, 5:207-213.
206. Van Den Bent M., Brandes A., Rampling R., et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group Study 26034. J Clin Oncol 2009, 27:1268-1274.
207. Vecht C.J., Hovestadt A., Verbiest H.B., et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994, 44:675-680.
208. Viola F., Katz A., Arantes A., et al. Phase II trial of high dose imatinib in recurrent glioblastoma multiforme (GBM) with platelet derived growth factor receptor (PDGFR) expression. J Clin Oncol 2007, 25:2056.
209. Vogelbaum M., Peereboom D., Stevens G., et al. Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: interim results. Proc Am Soc Clin Oncol 2004, 23:1558.
210. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13:1253-1259.
211. Walker M., Alexander E.J., Hunt W., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978, 49:333-343.
212. Walker M., Green S., Byar D., et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980, 303:1323-1329.
213. Walsh D.C., Kakkar A.K. Thromboembolism in brain tumors. Curr Opin Pulm Med 2001, 7:326-331.
214. Walter K.A., Tamargo R.J., Olivi A., et al. Intratumoral chemotherapy. Neurosurgery 1995, 37:1128-1145.
215. Wefel J.S., Lenzi R., Theriault R.L., et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004, 100:2292-2299.
216. Wen P., Toon T.S., Black P. Clinical Imaging, and laboratory diagnosis of brain tumors. brain tumors 2001, 24-50. Jones and Bartlett, New York. E. Laws, A. Kaye (Eds.).
217. Wen P., Chang S., Khun J., et al. Phase I study of erlotinib (Tarceva) and temsirolimus (CCI-779) for patients with recurrent malignant gliomas (NABTC 04-02) 2006.
218. Wen P.Y., Kesari S., Drappatz J. Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment. Expert Rev Anticancer Ther 2006, 6:733-754.
219. Wen P.Y., Schiff D., Kesari S., et al. Medical management of patients with brain tumors. J Neurooncol 2006, 80:313-332.
220. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006, 12:4899-4907.
221. Wen P.Y., Macdonald D.R., Reardon D.A., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28:1963-1972.
222. Wen P.Y., Prados M., Schiff D., et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2010, 28:2006.
223. Westphal M., Hilt D.C., Bortey E., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003, 5:79-88.
224. Wick W., Kuker W. Brain edema in neurooncology: radiological assessment and management. Onkologie 2004, 27:261-266.
225. Wong E.T., Hess K.R., Gleason M.J., et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999, 17:2572.
226. Yung A., Vredenburgh Cloughesy T., et al. Erlotinib HCl for glioblastoma multiforme in first relapse, a phase II trial. Proc Am Soc Clin Oncol 2004, 23:1555.
227. Yung W.K., Kyritsis A.P., Gleason M.J., et al. Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid. Clin Cancer Res 1996, 2:1931-1935.